Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial

The REACH Trial Investigators

Research output: Contribution to journalArticlepeer-review

379 Citations (Scopus)

Abstract

Background: VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. Methods: In this randomised, placebo-controlled, double-blind, multicentre, phase 3 trial (REACH), patients were enrolled from 154 centres in 27 countries. Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy, had Child-Pugh A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, had previously received sorafenib (stopped because of progression or intolerance), and had adequate haematological and biochemical parameters. Patients were randomly assigned (1:1) to receive intravenous ramucirumab (8 mg/kg) or placebo every 2 weeks, plus best supportive care, until disease progression, unacceptable toxicity, or death. Randomisation was stratified by geographic region and cause of liver disease with a stratified permuted block method. Patients, medical staff, investigators, and the funder were masked to treatment assignment. The primary endpoint was overall survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01140347. Findings: Between Nov 4, 2010, and April 18, 2013, 565 patients were enrolled, of whom 283 were assigned to ramucirumab and 282 were assigned to placebo. Median overall survival for the ramucirumab group was 9·2 months (95% CI 8·0-10·6) versus 7·6 months (6·0-9·3) for the placebo group (HR 0·87 [95% CI 0·72-1·05]; p=0·14). Grade 3 or greater adverse events occurring in 5% or more of patients in either treatment group were ascites (13 [5%] of 277 patients treated with ramucirumab vs 11 [4%] of 276 patients treated with placebo), hypertension (34 [12%] vs ten [4%]), asthenia (14 [5%] vs five [2%]), malignant neoplasm progression (18 [6%] vs 11 [4%]), increased aspartate aminotransferase concentration (15 [5%] vs 23 [8%]), thrombocytopenia (13 [5%] vs one [<1%]), hyperbilirubinaemia (three [1%] vs 13 [5%]), and increased blood bilirubin (five [2%] vs 14 [5%]). The most frequently reported (≥1%) treatment-emergent serious adverse event of any grade or grade 3 or more was malignant neoplasm progression. Interpretation: Second-line treatment with ramucirumab did not significantly improve survival over placebo in patients with advanced hepatocellular carcinoma. No new safety signals were noted in eligible patients and the safety profile is manageable. Funding: Eli Lilly and Co.

Original languageEnglish
Pages (from-to)859-870
Number of pages12
JournalThe Lancet Oncology
Volume16
Issue number7
DOIs
Publication statusPublished - 2015 Jul 1

Bibliographical note

Funding Information:
AXZ reports grants from Eli Lilly during the conduct of the study. J-FB reports personal fees from Eli Lilly during the conduct of the study. ADB reports personal fees from Eli Lilly, Bristol-Myers Squibb, and Genentech outside of the submitted work. TEFP reports grants from Eli Lilly during the conduct of the study and personal fees from Eli Lilly outside of the submitted work. TO reports grants and personal fees from Eli Lilly during the conduct of the study; personal fees from Eli Lilly; grants from Takeda Bio Development Center Ltd, Otsuka Pharmaceutical Co Ltd and grants from Glaxo Smith Kline K K; grants and personal fees from Kowa K K, Nippon Boehringer Ingelheim Co Ltd, Dainippon Simitomo Pharma Co Ltd, Pfizer Jana Inc, Taiho Pharmaceutical Co, Bayer Yakuhin Ltd, Chugai Pharmaceutical Co Ltd, Novartis Pharma K K, Yakuruto Honsha Co Ltd, Ono Pharmaceutical Co Ltd, Eisai Co Ltd, AstraZeneca K K, Merck Serono Co Ltd, Sceti Medical Labo K K, OncoTherapy Science Inc, and Kyowa Hakko Kirin Co Ltd outside of the submitted work. JT reports speaker and advisory board participance for Eli Lilly. JS reports personal fees from Roche, Merck, Bayer, Amgen, and Eli Lilly outside of the submitted work. IC reports personal fees from Eli Lilly during the conduct of the study; grants from Merck-Serono, personal fees from Bayer, personal fees from Bristol-Myers Squibb, personal fees from Gilead Science, personal fees from Taiho, and grants and personal fees from Roche outside of the submitted work. S-CC, PBA, and LY were employees and stockholders of Eli Lilly during the conduct of the study and have a provisional patent relevant to the work. JDS was an employee and stockholder of Eli Lilly during the conduct of the study. All other authors declare no competing interests.

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial'. Together they form a unique fingerprint.

Cite this